Legal & General Group PLC Myovant Sciences Ltd. Transaction History

Legal & General Group PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$24.03 - $27.02 $12,495 - $14,050	-520 Reduced 1.51%	33,829 $912,000
Q3 2022 Nov 14, 2022	SELL	$11.6 - $20.44 $170,485 - $300,406	-14,697 Reduced 29.97%	34,349 $617,000
Q2 2022 Aug 22, 2022	BUY	$7.78 - $14.69 $163,263 - $308,269	20,985 Added 74.78%	49,046 $610,000
Q1 2022 May 16, 2022	BUY	$11.38 - $16.4 $6,736 - $9,708	592 Added 2.16%	28,061 $373,000
Q3 2021 Nov 15, 2021	BUY	$18.94 - $26.99 $135,951 - $193,734	7,178 Added 35.38%	27,469 $616,000
Q1 2021 May 17, 2021	BUY	$20.46 - $25.18 $391,051 - $481,265	19,113 Added 1622.5%	20,291 $418,000
Q4 2020 Feb 12, 2021	SELL	$13.8 - $27.62 $18,105 - $36,237	-1,312 Reduced 52.69%	1,178 $33,000
Q4 2019 Feb 13, 2020	BUY	$4.2 - $19.21 $8,219 - $37,593	1,957 Added 367.17%	2,490 $39,000
Q4 2018 Feb 15, 2019	BUY	$15.01 - $25.2 $8,000 - $13,431	533 New	533 $9,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.